Cover Image
市場調查報告書

腰痛:開發中產品分析

Low Back Pain - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255955
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
腰痛:開發中產品分析 Low Back Pain - Pipeline Review, H1 2017
出版日期: 2017年05月09日 內容資訊: 英文 96 Pages
簡介

腰痛是肋骨以下與腿之間的任何部位都可能引起的症狀。腰痛的原因包含了過度勞累、姿勢不正、跌打損傷、老化、關節炎、脊椎相關疾病及癌症等。

本報告提供腰痛的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腰痛概要

治療藥的開發

  • 開發中產品的概要

腰痛:企業開發中的治療藥

腰痛:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

腰痛:企業開發中的產品

腰痛的治療藥的開發企業

  • Adynxx, Inc.
  • Aestus Therapeutics, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • Axsome Therapeutics, Inc.
  • Egalet Corporation
  • Frontier Biotechnologies Co., Ltd
  • Gador S.A.
  • Grunenthal GmbH
  • 久光製藥
  • Immune Pharmaceuticals Inc.
  • Kineta, Inc.
  • MEDRx Co., Ltd.
  • Mesoblast Limited
  • Nektar Therapeutics
  • Orion Oyj
  • Pacira Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Stayble Therapeutics AB

腰痛:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腰痛:最近的開發平台趨勢

腰痛:暫停中的計劃

腰痛:開發中止的產品

腰痛:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9227IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H1 2017, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 9, 2, 1 and 6 respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Low Back Pain - Overview
    • Low Back Pain - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Low Back Pain - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Low Back Pain - Companies Involved in Therapeutics Development
    • Ache Laboratorios Farmaceuticos SA
    • Adynxx Inc
    • AnGes MG Inc
    • Array BioPharma Inc
    • Axsome Therapeutics Inc
    • Boehringer Ingelheim GmbH
    • Egalet Corp
    • Frontier Biotechnologies Co Ltd
    • Gador SA
    • Grunenthal GmbH
    • Hisamitsu Pharmaceutical Co Inc
    • Huons Co Ltd
    • Immune Pharmaceuticals Inc
    • KPI Therapeutics Inc
    • MD Biosciences GmbH
    • Mesoblast Ltd
    • Nektar Therapeutics
    • Orion Oyj
    • Pacira Pharmaceuticals Inc
    • Pfizer Inc
    • Regeneron Pharmaceuticals Inc
    • Stayble Therapeutics AB
    • Sun Pharma Advanced Research Company Ltd
  • Low Back Pain - Drug Profiles
    • (acetaminophen + caffeine + diclofenac sodium + orphenadrine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (acetaminophen + tramadol hydrochloride) + eperisone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (loxoprofen + methocarbamol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AB-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARRY-954 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AYX-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bupivacaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cebranopadol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexmedetomidine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fasinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HP-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IG-8801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-22 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPC-06ID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NKTR-181 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxycodone hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPARC-1401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STA-363 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zoledronic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Low Back Pain - Dormant Projects
  • Low Back Pain - Discontinued Products
  • Low Back Pain - Product Development Milestones
    • Featured News & Press Releases
      • Mar 24, 2017: AnGes: Investigational New Drug (IND) Application Submitted to the FDA
      • Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
      • Mar 15, 2017: Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast's Cell Therapy
      • Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
      • Jul 25, 2016: Hisamitsu Pharmaceutical Announces the results of Phase II clinical study of HP-3150 in Japan for "Lower back pain" (an analgesic transdermal drug containing NSAIDs)
      • Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain
      • Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
      • Aug 28, 2015: Hisamitsu Pharmaceutical Announces commencement of the Phase II clinical study of HP-3150 in Japan for "Lower back pain" (an analgesic transdermal drug containing NSAIDs)
      • Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Low Back Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2017
  • Low Back Pain - Pipeline by Adynxx Inc, H1 2017
  • Low Back Pain - Pipeline by AnGes MG Inc, H1 2017
  • Low Back Pain - Pipeline by Array BioPharma Inc, H1 2017
  • Low Back Pain - Pipeline by Axsome Therapeutics Inc, H1 2017
  • Low Back Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Low Back Pain - Pipeline by Egalet Corp, H1 2017
  • Low Back Pain - Pipeline by Frontier Biotechnologies Co Ltd, H1 2017
  • Low Back Pain - Pipeline by Gador SA, H1 2017
  • Low Back Pain - Pipeline by Grunenthal GmbH, H1 2017
  • Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017
  • Low Back Pain - Pipeline by Huons Co Ltd, H1 2017
  • Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Low Back Pain - Pipeline by KPI Therapeutics Inc, H1 2017
  • Low Back Pain - Pipeline by MD Biosciences GmbH, H1 2017
  • Low Back Pain - Pipeline by Mesoblast Ltd, H1 2017
  • Low Back Pain - Pipeline by Nektar Therapeutics, H1 2017
  • Low Back Pain - Pipeline by Orion Oyj, H1 2017
  • Low Back Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2017
  • Low Back Pain - Pipeline by Pfizer Inc, H1 2017
  • Low Back Pain - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Low Back Pain - Pipeline by Stayble Therapeutics AB, H1 2017
  • Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Low Back Pain - Dormant Projects, H1 2017
  • Low Back Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Low Back Pain - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Low Back Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top